The estimated Net Worth of Daniel B Soland is at least $945 Tausend dollars as of 29 May 2024. Mr. Soland owns over 6,652 units of Acadia Pharmaceuticals Inc stock worth over $552,731 and over the last 10 years he sold ACAD stock worth over $0. In addition, he makes $392,439 as Independent Director at Acadia Pharmaceuticals Inc.
Sign up
Mr. Soland ACAD stock SEC Form 4 insiders trading
Daniel has made over 7 trades of the Acadia Pharmaceuticals Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 6,652 units of ACAD stock worth $106,099 on 29 May 2024.
The largest trade he's ever made was buying 50,000 units of Acadia Pharmaceuticals Inc stock on 18 June 2021 worth over $59,500. On average, Daniel trades about 4,432 units every 84 days since 2015. As of 29 May 2024 he still owns at least 34,654 units of Acadia Pharmaceuticals Inc stock.
You can see the complete history of Mr. Soland stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Daniel Soland biography
Daniel B. Soland is Independent Director of the Company. Mr. Soland has served as a director of our company since March 2015. Mr. Soland served as Chief Executive Officer of uniQure N.V., a human gene therapy company, from December 2015 until September 2016. Mr. Soland previously served as Senior Vice President and Chief Operating Officer of ViroPharma, Inc. starting in 2008 until it was acquired in 2014, and as Vice President and Chief Commercial Officer of ViroPharma from 2006 to 2008. During his tenure at ViroPharma, Mr. Soland managed the commercial, manufacturing and quality organizations, helped build the company’s commercial infrastructure in the United States, Europe, and Canada and led the launch of Cinryze®, one of the most successful ultra-orphan drugs in the United States. Mr. Soland served as President, Chiron Vaccines, of Chiron Corporation from 2005 to 2006 and led the growth of the vaccine business to over $1 billion in sales. From 2002 through 2005, Mr. Soland served as President and Chief Executive Officer of Epigenesis Pharmaceuticals. Earlier in his career, Mr. Soland worked for GlaxoSmithKline in increasing roles of responsibility from 1993 to 2002, including as Vice President and Director, Worldwide Marketing Operations, GSK Biologicals. He currently serves on the board of directors of DBV Technologies S.A. and KalVista Pharmaceuticals, Inc. Mr. Soland holds a B.S. in pharmacy from the University of Iowa.
What is the salary of Daniel Soland?
As the Independent Director of Acadia Pharmaceuticals Inc, the total compensation of Daniel Soland at Acadia Pharmaceuticals Inc is $392,439. There are 8 executives at Acadia Pharmaceuticals Inc getting paid more, with Stephen Davis having the highest compensation of $7,631,250.
How old is Daniel Soland?
Daniel Soland is 62, he's been the Independent Director of Acadia Pharmaceuticals Inc since 2015. There are 3 older and 12 younger executives at Acadia Pharmaceuticals Inc. The oldest executive at Acadia Pharmaceuticals Inc is Edmund Harrigan, 67, who is the Independent Director.
What's Daniel Soland's mailing address?
Daniel's mailing address filed with the SEC is C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO, CA, 92130.
Insiders trading at Acadia Pharmaceuticals Inc
Over the last 20 years, insiders at Acadia Pharmaceuticals Inc have traded over $21,409,958 worth of Acadia Pharmaceuticals Inc stock and bought 29,279,665 units worth $647,484,672 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B... und Carl L Gordon. On average, Acadia Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $2,248,934. The most recent stock trade was executed by Mark C. Schneyer on 16 August 2024, trading 9,733 units of ACAD stock currently worth $148,720.
What does Acadia Pharmaceuticals Inc do?
acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies
What does Acadia Pharmaceuticals Inc's logo look like?
Complete history of Mr. Soland stock trades at Acadia Pharmaceuticals Inc, DBV Technologies, Idera Pharmaceuticals und KalVista Pharmaceuticals Inc
Acadia Pharmaceuticals Inc executives and stock owners
Acadia Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Stephen Davis,
Director and Chief Executive Officer -
Srdjan Stankovic,
President -
Michael Yang,
Executive Vice President, Chief Commercial Officer -
Elena Ridloff,
Executive Vice President, Chief Financial Officer -
Austin Kim,
Executive Vice President, General Counsel, and Secretary -
Stephen R. Davis J.D.,
CEO & Director -
Dr. Srdjan R. Stankovic,
Pres -
Austin D. Kim,
Exec. VP, Gen. Counsel & Sec. -
Daniel Soland,
Independent Director -
James Daly,
Independent Director -
Edmund Harrigan,
Independent Director -
Stephen Biggar,
Independent Chairman of the Board -
Laura Brege,
Independent Director -
Julian Baker,
Independent Director -
Mark Johnson,
Vice President, Investor Relations -
Elizabeth Garofalo,
Director -
James Kihara,
Principal Accounting Officer -
Ponni Subbiah,
Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer -
Mark Schneyer,
Senior Vice President, Business Development and Chief Business Officer -
Stephanie Fagan,
Senior Vice President - Corporate Affairs, Chief Communications Officer -
Gudarz Davar,
Executive Vice President - Head of Research and Development -
Julie Fisher,
Sr. VP of Marketing & Commercial Strategy -
Dr. Kathie M. Bishop Ph.D.,
Sr. VP, Chief Scientific Officer & Head of Rare Disease -
Bob Mischler,
Sr. VP of Strategy & Technology Operations -
James K. Kihara,
VP, Corp. Controller & Principal Accounting Officer -
Brendan Teehan,
Exec. VP, COO & Head of Commercial -
Bros. Advisors Lpbaker Feli...,
-
Mary Ann Gray,
Director -
Terrence O Moore,
EVP, CHIEF COMMERCIAL OFFICER -
L.P.667, L.P.Baker Bros. Ad...,
-
Leslie L Iversen,
-
Bros. Advisors Lp667, L.P.B...,
-
Bros. Advisors Lp14159, L.P...,
-
Todd S. Young,
EVP AND CFO -
Roger Mills,
Executive VP, Development -
Uli Hacksell,
Chief Executive Officer -
Michael T Borer,
Director -
Thomas H Aasen,
VP, CFO, Sec. Treas. -
Lester J Ph D Kaplan,
Director -
Torsten Rasmussen,
Director -
Robert E Davis,
Exec. VP, Drug Discovery -
William Mc Dowall Wells,
-
Bros Advisors Llcbaker Feli...,
-
Bioscience Partners Iv Lpmr...,
-
Osch Martien Van,
Director -
Bioscience Partners Iv Lpob...,
-
Carl L Gordon,
Director -
Felixbaker Julianbaker Bros...,
-
Mark R Brann,
Pres., Chf. Scientific Officer -
Alan Walton,
Director -
Glenn Baity,
EVP AND GC -
Bo Ragnar Tolf,
VP Chm/Mng Dir ACADIA Phrm A/S -
Gordon M Binder,
Director -
Brian Lundstrom,
Sr. VP. Business Development -
John Joseph Kaiser,
VP, Strat. Mrkting & Com. Dev. -
Adora Ndu,
-
Brendan Teehan,
EVP, COO, HEAD OF COMMERCIAL -
Douglas J Williamson,
Executive VP, Research & Dev -
Bros. Advisors Lp667, L.P.B...,
-
Jennifer J Rhodes,
EVP, CHIEF LEGAL OFFICER, SEC -
Elizabeth H.Z. Thompson,
EVP, Head of Research & Dev